Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Journey Medical Corporation (DERM : NSDQ)

• Company Description    Journey Medical Corporation is a commercial-stage pharmaceutical company. It focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Journey Medical Corporation is based in Scottsdale, Arizona. Number of Employees: 41

• Price / Volume Information    Yesterday's Closing Price: $7.70 Daily Weekly Monthly 20 Day Moving Average: 133,425 shares Shares Outstanding: 27.14 (millions) Market Capitalization: $208.95 (millions) Beta: 0.80 52 Week High: $9.40 52 Week Low: $3.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.13% -1.99% 12 Week 5.48% 3.58% Year To Date 96.93% 69.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9237 E VIA DE VENTURA BLVD. SUITE 105 - SCOTTSDALE,AZ 85258 USA ph: 480-434-6670 fax: - ir@jmcderm.com http://www.jmcderm.com

• General Corporate Information    Officers Claude Maraoui - Chief Executive Officer; President and Director Lindsay A. Rosenwald - Executive Chairman Joseph Benesch - Chief Financial Officer Neil Herskowitz - Director Justin Smith - Director Peer Information Journey Medical Corporation (GSAC) Journey Medical Corporation (CASI) Journey Medical Corporation (ALCD.) Journey Medical Corporation (OMNN) Journey Medical Corporation (CGPI.) Journey Medical Corporation (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 48115J109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/25/26 Share - Related Items Shares Outstanding: 27.14 Most Recent Split Date: (:1) Beta: 0.80 Market Capitalization: $208.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.48 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/25/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.84 Price/Cash Flow: - Price / Sales: 3.52 EPS Growth vs. Year Ago Period: 25.00% vs. Previous Quarter: 43.75% Sales Growth vs. Year Ago Period: 20.52% vs. Previous Quarter: 17.47% ROE 09/30/25 - -39.94 06/30/25 - -48.69 03/31/25 - -52.03 ROA 09/30/25 - -10.45 06/30/25 - -11.26 03/31/25 - -11.28 Current Ratio 09/30/25 - 1.42 06/30/25 - 1.27 03/31/25 - 1.34 Quick Ratio 09/30/25 - 1.12 06/30/25 - 0.95 03/31/25 - 1.03 Operating Margin 09/30/25 - -14.58 06/30/25 - -15.49 03/31/25 - -14.76 Net Margin 09/30/25 - -14.58 06/30/25 - -15.49 03/31/25 - -14.76 Pre-Tax Margin 09/30/25 - -14.38 06/30/25 - -15.28 03/31/25 - -14.65 Book Value 09/30/25 - 0.98 06/30/25 - 0.82 03/31/25 - 0.93 Inventory Turnover 09/30/25 - 1.56 06/30/25 - 1.46 03/31/25 - 1.63 Debt-to-Equity 09/30/25 - 0.75 06/30/25 - 1.11 03/31/25 - 1.07 Debt-to-Capital 09/30/25 - 43.00 06/30/25 - 52.60 03/31/25 - 51.75

Powered by Zacks Investment Research ©